Pay in 4 interest-free payments of $6.63 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Tesamorelin has the strongest evidence specifically for reducing visceral adipose tissue
Taken in conjunction with previous results, it suggests that while GLP1R and GR agonism in conjunction is able to produce large decreases in weight (Via the reduction of food intake and increased energy expenditure), but the absence of GIPR agonism produces a more unfavourable frequency of side-effects
Brighten your skin effectively and safely
Originally approved by the FDA for the treatment of adult obesity in 2014, the drug received authorisation in 2020 for obesity in adolescents aged 12-17 years old (Mller, Blher, Tschp, DiMarchi)
World population projected to reach 9.8 billion in 2050 and 11.2 billion in 2100 (2025)
US$ 20.00
US$ 27.84
US$ 27.81
US$ 24.60
US$ 24.72
US$ 24.86
